OR WAIT null SECS
Tim Sturgeon is a senior analyst at Results Healthcare.
Contract manufacturers prepare for anticipated biosimilars manufacturing demands through expansion and acquisition.
Compared to traditional small-molecule generics, the R&D costs and development times for biosimilars are significantly greater. With demand for services in the biosimilars space set to soar, many contract development and manufacturing organizations are increasing their capabilities in this field. Expansions including in-house development, partnerships and joint ventures, or bolt-on acquisitions are summarized.
Download BioPharm International's